Curanex Pharmaceuticals Inc (CURX) — 10-Q Filings
All 10-Q filings from Curanex Pharmaceuticals Inc. Browse 2 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (2)
-
Curanex's R&D Surge Drives Losses, IPO Boosts Cash to $5.8M
— Nov 17, 2025 Risk: medium
Curanex Pharmaceuticals Inc. (CURX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $1,151,988, a substantial -
Curanex Losses Mount, IPO Funds Ulcerative Colitis Drug Development
— Sep 9, 2025 Risk: high
Curanex Pharmaceuticals Inc. (CURX) reported a net loss of $197,929 for the six months ended June 30, 2025, a significant increase from the $124,401 net loss fo
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX